This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

New Data Show That Women With Uterine Fibroids Experienced Significant And Long-Term Improvement In Their Symptoms With The Acessa™ Procedure

LIVERMORE, Calif., Nov. 12, 2013 /PRNewswire/ -- Halt Medical today announced that data from a large multi-center clinical study of the Acessa™ Procedure showed that women with uterine fibroids experienced significant and long-term improvement in their symptoms and for 95 percent of women, use of this procedure did not require further fibroid treatment during the two-year study follow-up. Results from The Halt Fibroid Study were presented today at the 42nd AAGL Global Congress on Minimally Invasive Gynecology near Washington, D.C. The AAGL is the world's premiere professional society dedicated to minimally invasive surgery in gynecology.

According to the National Institutes of Health, uterine fibroids are a common condition affecting at least 70 percent of all women by age 50. The size of fibroids can vary greatly, ranging from microscopic to the size of a melon. And symptoms may vary widely from prolonged and heavy menstrual blood flow and bloating to pelvic pain, cramping, and anemia. While fibroids are nearly always noncancerous, they are most often treated by the complete removal of the uterus in a hysterectomy procedure.

The population under study included 135 women with ≤ 6 treatable fibroids and heavy menstrual bleeding who were treated with the Acessa Procedure and followed for 24 months. Patients participating in the study quickly experienced significant improvement in their symptom severity; these results were sustained over two years with the symptom severity scores decreasing significantly compared to the pretreatment scores. The overall incidence of adverse events and retreatment rates were low.

Women with fibroids often are self-conscious, concerned about their health and lack the energy to participate in physical or social activities. The Halt Fibroid Study also found that many women treated with Acessa experienced substantial improvements in how they felt about their condition and themselves as early as three months following the procedure, with results maintained for two years. Importantly, health-related quality of life (HRQL) scores increased significantly by 41 percent when compared to the baseline measurement. Additionally, HRQL sub-scores also improved significantly from baseline to 24 months in all categories (concern, activities, energy/mood, control, self-consciousness, and sexual function).

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,273.41 +82.04 0.48%
S&P 500 2,002.11 -0.05 -0.00%
NASDAQ 4,629.9720 -8.0220 -0.17%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs